CGEM

Cullinan Oncology LLC

(NO DISGNOSTIC SUBSTANCES)
LIFE SCIENCES

Prices are adjusted according to historical splits.

Cullinan Oncology LLC Stock Price

Vitals

Today's Low:
$12.6800
Today's High:
$13.5500
Open Price:
$13.1200
52W Low:
$7.3
52W High:
$23.92
Prev. Close:
$13.2600
Volume:
183961

Company Statistics

Market Cap.:
$0.590 billion
Book Value:
13.32
Revenue TTM:
$0.000 billion
Operating Margin TTM:
0%
Gross Profit TTM:
$0.019 billion
Gross Profit TTM:
$0.019 billion
Profit Margin:
0%
Return on Assets TTM:
-12.6%
Return on Equity TTM:
20.4%

Company Profile

Cullinan Oncology LLC had its IPO on 2021-01-08 under the ticker symbol CGEM.

The company operates in the LIFE SCIENCES sector and (NO DISGNOSTIC SUBSTANCES) industry. Cullinan Oncology LLC has a staff strength of 0 employees.

Stock update

Shares of Cullinan Oncology LLC opened at $13.12 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $12.68 - $13.55, and closed at $12.93.

This is a -2.49% slip from the previous day's closing price.

A total volume of 183,961 shares were traded at the close of the day’s session.

In the last one week, shares of Cullinan Oncology LLC have slipped by -0.54%.

Cullinan Oncology LLC's Key Ratios

Cullinan Oncology LLC has a market cap of $0.590 billion, indicating a price to book ratio of 1.028 and a price to sales ratio of 26.88.

In the last 12-months Cullinan Oncology LLC’s revenue was $0.000 billion with a gross profit of $0.019 billion and an EBITDA of $-0.114 billion. The EBITDA ratio measures Cullinan Oncology LLC's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Cullinan Oncology LLC’s operating margin was 0% while its return on assets stood at -12.6% with a return of equity of 20.4%.

In Q2, Cullinan Oncology LLC’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Cullinan Oncology LLC’s PE and PEG Ratio

Forward PE
6.3
Trailing PE
5.43
PEG
None

Its diluted EPS in the last 12-months stands at $2.38 per share while it has a forward price to earnings multiple of 6.3 and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cullinan Oncology LLC’s profitability.

Cullinan Oncology LLC stock is trading at a EV to sales ratio of 11.55 and a EV to EBITDA ratio of -0.0929. Its price to sales ratio in the trailing 12-months stood at 26.88.

Cullinan Oncology LLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Cullinan Oncology LLC ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Cullinan Oncology LLC ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Cullinan Oncology LLC’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Cullinan Oncology LLC's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Cullinan Oncology LLC paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$12.93
52-Week High
$23.92
52-Week Low
$7.3
Analyst Target Price
$34

Cullinan Oncology LLC stock is currently trading at $12.93 per share. It touched a 52-week high of $23.92 and a 52-week low of $23.92. Analysts tracking the stock have a 12-month average target price of $34.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Cullinan Oncology LLC

The stock symbol (also called stock or share ticker) of Cullinan Oncology LLC is CGEM

The IPO of Cullinan Oncology LLC took place on 2021-01-08

Similar Industry Stocks ((NO DISGNOSTIC SUBSTANCES))

Last Price
Chg
Chg%
$0.91
0.14
+17.95%
$1.29
-0.06
-4.44%
Agenus Inc (AGEN)
$2.43
-0.08
-3.19%
$18.96
-0.51
-2.62%
$2.6
-0.02
-0.76%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company is headquartered in Cambridge, Massachusetts.

Address

ONE MAIN STREET, SUITE 520, CAMBRIDGE, MA, US